EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects

Shawn Flanagan iD, Voon Ong iD, Thomas Marbury iD, Alena Jandourek, Ronak G Gandhi iD, Taylor Sandison

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024

DOI: 10.1002/phar.2943 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Verfasst von Shawn Flanagan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cidara Therapeutics, Inc., San Diego, California, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Echinocandins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cidara Therapeutics, Melinta Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Rezafungin is a second‐generation, once‐weekly echinocandin antifungal approved for the treatment of invasive candidiasis, including candidemia. In phase II/III studies of rezafungin versus caspofungin, patients with severe hepatic impairment were excluded due to lack of caspofungin data in this population. This open‐label, single‐dose, phase I study evaluated the pharmacokinetics (primary objective) and safety of rezafungin in subjects with moderate or severe hepatic impairment versus matched, healthy subjects with normal hepatic function.

Methods

Eight subjects each with moderate (Child‐Pugh B) or severe (Child‐Pugh C) hepatic impairment were matched 1:1 with healthy subjects for age, sex, and body mass index. Each subject received a single 400‐mg, intravenous, 1‐h infusion of rezafungin. Plasma pharmacokinetic sampling was performed at various time points through 336 h postdose. Pharmacokinetic parameters were derived by non‐compartmental analysis. Safety was assessed throughout.

Results

All 32 subjects received study treatment and were included in all analyses. Despite overlapping distributions of total plasma concentrations, based on geometric least‐squares (LS) mean ratios, the area under the plasma concentration–time curve from time zero (prior to the start of infusion) to infinity (AUC 0–∞ ) was 32% lower in subjects with moderate (LS mean ratio, 67.55; 90% confidence interval [CI]: 53.91, 84.65) and severe (LS mean ratio, 67.84; 90% CI: 57.49, 80.05) hepatic impairment versus matched healthy subjects. The maximum plasma concentration ( C max ) was 12% lower in moderate hepatic impairment and 28% lower in severe hepatic impairment groups. Linear regression showed no significant trend in the degree of hepatic impairment (based on Child‐Pugh score) on AUC 0–∞ or C max ( p > 0.05). Treatment‐emergent adverse events were reported in seven subjects (21.9%; three subjects in each of the hepatic impairment groups, and one healthy subject), none of which were severe, serious, or resulted in withdrawal.

Conclusions

Rezafungin is well tolerated and can be administered to patients with moderate or severe hepatic impairment without the need for dose adjustment. The modest reduction in exposures in subjects with hepatic impairment is not clinically meaningful and is unlikely to impact efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsEchinocandinsHumansMaleFemaleMiddle AgedAdultAgedLiver DiseasesInfusions, IntravenousArea Under CurveSeverity of Illness IndexCase-Control Studies

Stichwörter der Autor:innen

hepatic impairmentpharmacokineticsrezafunginsafety

Substanzen

Antifungal AgentsEchinocandinsRezafungin

Autor:innen und Institutionen

  • Cidara Therapeutics, Inc., San Diego, California, USA.
  • Orlando Clinical Research Center, Orlando, Florida, USA.
  • Melinta Therapeutics, LLC, Parsippany, New Jersey, USA.

ORCID-Profile: Shawn Flanagan, Voon Ong, Thomas Marbury, Ronak G Gandhi

Förderung

  • Cidara Therapeutics
  • Melinta Therapeutics

Zitieren

APA

Flanagan, S., Ong, V., Marbury, T., Jandourek, A., Gandhi, R. G., & Sandison, T. (2024). Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2943

Vancouver

Flanagan S, Ong V, Marbury T, Jandourek A, Gandhi RG, Sandison T. Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.2943

BibTeX
@article{Flanagan2024,
  author = {Flanagan, Shawn and Ong, Voon and Marbury, Thomas and Jandourek, Alena and Gandhi, Ronak G and Sandison, Taylor},
  title = {Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2024},
  doi = {10.1002/phar.2943}
}
Kostenlos starten →